introductiona
dysregul
immun
respons
lead
sepsi
frequent
caus
late
posttraumat
death
found
novel
antiinflammatori
pathway
initi
acut
phase
protein
creactiv
protein
crp
interact
receptor
monocyt
pathway
protect
anim
model
endotoxin
shock
hypothes
genet
polymorph
might
contribut
monocyt
respons
suscept
infecti
complic
sever
trauma
methodsw
conduct
observ
studi
prospect
identifi
cohort
adult
patient
conveni
enrol
admit
sever
trauma
enrol
patient
collect
blood
sampl
enrol
hr
patient
follow
hospit
stay
septic
event
day
record
cytokin
crp
level
determin
plasma
three
blood
draw
addit
dna
extract
blood
analyz
hr
polymorph
strongli
affect
bind
igg
crp
receptor
resultselev
level
well
crp
associ
reduc
time
posttraumat
sepsi
cox
regress
analysi
express
monocyt
hladr
patient
monocyt
also
associ
sepsi
hr
ci
genet
analysi
found
individu
polymorph
receptor
bind
crp
poorli
also
like
decreas
monocyt
hladr
posttraumat
sepsi
vitro
studi
show
crp
could
attenu
monocyt
deactiv
volunt
polymorph
receptor
bind
crp
conclusionsour
find
suggest
common
genet
variat
receptor
may
contribut
infecti
suscept
trauma
patient
vitro
experi
suggest
associ
relat
inabl
crp
bind
receptor
variant
keyword
posttraumat
sepsi
monocyt
deactiv
c
reactiv
protein
receptor
other
found
correl
posttraumat
sepsi
individu
signific
monocyt
deactiv
follow
traumat
injuri
monocyt
deactiv
patient
character
lack
tumor
necrosi
factor
tnf
west
et
al
traumat
injuri
lead
caus
death
person
year
age
death
secondari
massiv
hemorrhag
sever
brain
injuri
howev
victim
surviv
initi
trauma
resuscit
remain
risk
sepsi
sepsisassoci
multiorgan
failur
fact
traumarel
death
associ
posttraumat
sepsi
acquir
hospit
day
week
follow
sever
injuri
although
pattern
sever
injuri
help
identifi
patient
high
risk
develop
sepsi
clinic
factor
alon
account
develop
posttraumat
sepsi
posttraumat
sepsi
respons
prolong
length
icu
stay
increas
rate
organ
failur
remain
lead
caus
death
patient
surviv
initi
resuscit
larg
retrospect
analysi
sever
injur
patient
germani
reveal
overal
incid
posttraumat
sepsi
sever
injur
patient
overal
mortal
trauma
patient
decreas
studi
period
mortal
rate
subgroup
septic
trauma
patient
significantli
decreas
angu
et
al
estim
averag
cost
per
case
annual
total
cost
billion
nation
review
nation
case
consequ
posttraumat
sepsi
remain
signific
problem
requir
research
earli
identif
patientspecif
characterist
associ
develop
may
help
earli
identif
complic
time
intervent
improv
clinic
outcom
caus
sepsi
multifactori
acut
injuri
risk
factor
mani
intervent
doctor
nurs
use
treat
acut
injur
patient
prevent
intervent
qualiti
control
program
hospit
care
surviv
sepsi
campaign
cdc
monitor
effort
done
much
last
ten
year
increas
awar
sepsi
effort
target
earli
identif
risk
patient
sinc
earli
aggress
treatment
sepsi
increas
chanc
surviv
effort
mortal
rate
sepsi
declin
yet
risk
sepsi
remain
high
particularli
trauma
patient
sever
injuri
identifi
predict
factor
associ
posttraumat
sepsi
may
next
step
improv
care
trauma
patient
product
upon
lp
challeng
vitro
increas
product
antiinflammatori
cytokin
markedli
reduc
hladr
express
result
loss
antigenpres
capac
monocyt
reduc
hladr
express
describ
trauma
patient
failur
return
normal
level
hladr
express
correl
higher
mortal
sever
injur
trauma
patient
mechan
surround
monocyt
deactiv
revers
fulli
recogn
receptor
famili
receptor
express
innat
immun
effector
cell
set
threshold
cell
activ
immun
complex
consist
one
inhibitori
sever
activ
receptor
differ
affin
specif
immunoglobulin
ig
subclass
leukocyt
function
includ
antibodydepend
cellular
cytotox
phagocytosi
superoxid
gener
degranul
cytokin
product
regul
antibodi
product
essenti
host
defens
immun
regul
interact
influenc
sever
factor
may
affect
express
level
activ
inhibitori
chang
affin
receptor
creactiv
protein
crp
acut
phase
serum
protein
share
sever
function
igg
includ
complement
activ
bind
fc
receptor
monocyt
neutrophil
crp
bind
microbi
antigen
damag
cell
opson
particl
phagocytosi
regul
inflammatori
respons
induct
cytokin
synthesi
activ
crp
depend
abil
activ
complement
bind
crp
bind
three
type
iga
receptor
freshli
isol
monocyt
primarili
bind
crp
play
central
role
regul
immun
autoimmun
initi
local
inflamm
gene
contain
function
singl
nucleotid
polymorph
snp
point
mutat
result
arginin
r
histidin
h
posit
igbind
domain
polymorph
known
affect
receptor
affin
specif
interestingli
r
variant
show
strong
bind
crp
weak
bind
igg
wherea
h
variant
show
weak
bind
crp
strong
bind
igg
polymorph
clinic
implic
may
repres
risk
factor
certain
diseas
either
level
diseas
suscept
level
diseas
sever
patient
r
allel
found
sever
case
sever
acut
respiratori
syndrom
infect
like
suscept
encapsul
organ
infect
attribut
poor
bind
r
variant
polymorph
describ
herit
risk
factor
autoimmun
infecti
diseas
hypothes
common
genet
variat
receptor
crp
might
contribut
individu
differ
monocyt
respons
suscept
infecti
complic
sever
trauma
human
research
review
committe
univers
new
mexico
health
scienc
center
approv
protocol
prior
sampl
collect
patient
elig
enrol
includ
sever
injur
trauma
patient
defin
iss
greater
requir
icu
admiss
age
greater
year
neg
pregnanc
test
patient
enrol
admit
icu
mere
observ
statu
patient
treat
immunosuppress
steroid
patient
follow
hospit
stay
septic
event
occur
within
day
admiss
record
defin
system
inflammatori
respons
syndrom
sir
criteria
confirm
posit
cultur
clinic
confirm
infect
sever
sepsi
defin
document
infect
acut
organ
dysfunct
subset
studi
patient
popul
previous
character
subject
character
studi
part
ongo
effort
better
understand
chang
immun
function
sever
trauma
sampl
collectionstudi
design
conveni
sampl
patient
enrol
limit
weekday
due
personnel
constraint
prospect
identifi
patient
met
enrol
criteria
blood
sampl
collect
elig
patient
enrol
day
approxim
hour
day
hour
day
provid
inform
consent
consent
legal
author
repres
whole
blood
collect
day
heparin
tube
determin
plasma
cytokin
level
edta
tube
day
determin
monocyt
marker
flow
cytometri
dna
extract
septic
event
record
enrol
patient
day
hospit
defin
presenc
sir
criteria
confirm
posit
cultur
combin
appropri
clinic
find
ie
document
cours
antibiot
treatment
clinic
presum
infect
posit
cultur
consid
sepsi
group
emr
evalu
determin
appropri
clinic
criteria
present
ietachycardia
fever
leukocytosi
andor
tachypnea
determin
presenc
sir
criteria
well
document
treat
physician
clinic
infect
multipl
organ
dysfunct
syndrom
mod
defin
organ
failur
least
two
organ
system
organ
failur
defin
sequenti
organ
failur
assess
criteria
sofa
score
point
icu
stay
subset
studi
patient
popul
previous
character
previous
describ
associ
hemeoxygenas
monocyt
deactiv
show
correl
monocyt
deactiv
subset
cohort
identifi
expans
subpopul
monocyt
portion
cohort
final
describ
correl
lower
apolipoprotein
b
aii
level
nosocomi
infect
portion
cohort
plasma
cytokin
analysisheparin
blood
sampl
day
centrifug
rpm
minut
plasma
collect
store
later
determin
cytokin
concentr
factor
level
plasma
cytokin
concentr
determin
milliplex
human
cytokin
immunoassay
accord
manufactur
instruct
millipor
billerica
cytokin
measur
techniqu
includ
tnfalpha
crp
mcsf
solubl
concentr
determin
separ
elisa
accord
manufactur
instruct
r
system
minneapoli
mn
crp
mcsf
solubl
bd
bioscienc
san
jose
ca
dna
extract
determin
polymorphismwhol
blood
collect
patient
enrol
control
volunt
store
futur
dna
extract
dna
extract
perform
use
qiagen
dneasi
blood
kit
accord
manufactur
instruct
qiagen
inc
valencia
ca
determin
polymorph
genom
dna
extract
edta
anticoagul
whole
blood
gentra
system
inc
plymouth
mn
genotyp
determin
use
allelespecif
pcr
reaction
character
presenc
absenc
histidin
h
arginin
r
allel
allel
forward
pcr
primer
use
bind
sequenc
intron
uniqu
gene
togeth
either
revers
primer
previous
report
polymorph
genom
dna
extract
describ
valin
v
phenylanalin
f
polymorph
evalu
directli
sequenc
dna
prepar
commerci
purchas
primer
sigma
st
loui
mo
accord
genewiz
genewiz
inc
south
plainfield
nj
sampl
submiss
guidelin
monocyt
surfac
marker
expressionexpress
hladr
patient
monocyt
volunt
monocyt
determin
flow
cytometri
previous
describ
briefli
whole
blood
sampl
collect
donor
edtatr
tube
hour
use
measur
follow
mab
use
fitc
miltenyi
biotec
san
diego
ca
antihladr
bd
bioscienc
san
jose
ca
correspond
isotyp
control
cell
incub
mab
minut
dark
rbc
lyse
ml
rbc
lysi
solut
ebiosci
san
diego
ca
room
temperatur
minut
cell
wash
phosphat
buffer
salin
pb
twice
ml
pab
bsa
sodium
azid
pb
stain
buffer
cell
fix
paraformaldehyd
fluoresc
sampl
analyz
flow
cytomet
bd
bioscienc
san
jose
ca
flowjo
softwar
tree
star
inc
ashland
result
express
percentag
hladr
express
cell
subtract
correspond
isotyp
control
deactiv
control
monocytesth
use
human
peripher
blood
monocyt
healthi
donor
approv
human
research
review
committe
univers
new
mexico
health
scienc
center
blood
healthi
volunt
drawn
heparin
tube
peripher
blood
mononuclear
cell
pbmc
obtain
gradient
separ
use
ficol
paqu
plu
ge
healthcar
pittsburgh
pa
briefli
ml
whole
blood
dilut
pb
care
layer
ml
ficol
paqu
plu
sampl
centrifug
rpm
minut
mononuclear
cell
layer
collect
pbmc
wash
two
time
pb
resuspend
medium
contain
heatinactiv
fbshyclon
sigma
st
loui
mo
control
pbmc
incub
hour
stimul
lp
ngml
hour
acut
phase
level
heataggreg
crp
ad
time
lp
appropri
well
addit
hour
incub
supernat
collect
store
futur
determin
product
elisa
bd
bioscienc
san
jose
ca
accord
manufactur
instruct
cell
remov
collect
multipl
wash
pb
hladr
express
determin
flow
cytometri
cultur
control
pbmc
describ
patient
monocyt
statist
analysisgraph
statist
analys
perform
use
prism
softwar
version
graphpad
la
jolla
ca
sa
version
statist
analysi
softwar
cari
nc
univari
analys
conduct
biomark
measur
septic
complic
patient
mannwhitney
u
test
use
compar
continu
variabl
fisher
exact
test
use
compar
categor
variabl
unadjust
adjust
cox
model
regress
analys
use
assess
associ
biomark
time
sepsi
adjust
model
includ
iss
score
transfus
addit
biomark
iss
model
quadrat
polynomi
effect
center
iss
iss
iss
transfus
patient
transfus
otherwis
patient
follow
censor
day
patient
develop
sepsi
biomark
skew
distribut
transform
analys
use
base
logarithm
transform
hazard
ratio
one
unit
increas
biomark
correspond
effect
size
doubl
biomark
concentr
longitudin
chang
biomark
concentr
assess
mix
model
regress
analys
term
day
initi
blood
draw
iss
whether
patient
develop
sepsi
within
day
patientlevel
random
effect
use
account
repeat
measur
mannwhitney
u
test
use
compar
valu
volunt
monocyt
product
hladr
express
associ
genotyp
sepsi
assess
use
cochranarmitag
exact
trend
test
cox
model
regress
genet
model
cox
regress
use
number
h
copi
hhrh
versu
rr
assess
associ
sepsi
statist
signific
determin
p
adjust
multipl
hypothes
test
made
control
fals
discoveri
rate
thirti
patient
develop
sepsi
studi
period
characterist
studi
popul
note
tabl
averag
iss
rang
averag
age
year
rang
signific
differ
incid
sepsi
mechan
trauma
ie
blunt
vs
penetr
patient
develop
posttraumat
sepsi
significantli
like
receiv
blood
transfus
first
hour
resuscit
patient
develop
sepsi
studi
period
tabl
fiftyseven
percent
transfus
patient
develop
sepsi
vs
patient
transfus
fortyseven
patient
percent
intub
patient
percent
intub
hour
rang
day
sever
sepsi
document
patient
seven
patient
develop
mod
three
patient
die
studi
period
median
day
infect
hospit
day
occur
earli
hospit
day
specif
foci
infect
pneumonia
urinari
tract
infect
bacteremia
clostridium
dificil
coliti
intraabdomin
abscess
four
patient
develop
infect
multipl
site
caus
bacteria
primarili
gramneg
one
patient
mix
bacteri
infect
fourteen
treat
empir
antibiot
seven
treat
periop
prophylact
antibiot
although
approach
signific
find
statist
signific
differ
incid
sepsi
use
antibiot
patient
receiv
antibiot
vs
receiv
antibiot
p
length
antibiot
administr
prior
septic
event
vari
major
given
hour
septic
event
occur
four
patient
diagnosi
sepsi
made
patient
receiv
empir
antibiot
therapi
median
level
cytokin
biomark
measur
day
blood
draw
list
tabl
perform
separ
unadjust
adjust
cox
model
regress
analys
cytokin
measur
day
presenc
septic
complic
prior
day
hospit
figur
adjust
analys
chose
adjust
injuri
sever
score
need
blood
transfus
signific
factor
develop
posttraumat
sepsi
analyz
clinic
factor
includ
hypotens
adjust
sinc
transfus
model
predict
sepsi
well
hypotens
model
antiinflammatori
cytokin
associ
increas
risk
develop
sepsi
similarli
proinflammatori
cytokin
chemokin
well
acut
phase
protein
crp
associ
increas
risk
develop
sepsi
unadjust
analysi
adjust
clinic
factor
iss
need
transfus
crp
remain
associ
sepsi
figur
control
fals
discoveri
associ
time
sepsi
three
biomark
signific
also
explor
time
cours
biomark
concentr
use
mix
model
regress
analys
patient
ultim
develop
sepsi
significantli
higher
concentr
crp
initi
measur
compar
develop
sepsi
crp
concentr
continu
increas
time
p
trend
similar
sepsi
nonsepsi
patient
p
decreas
time
p
rate
decreas
faster
sepsi
patient
nonsepsi
patient
p
sever
injur
patient
cohort
found
hladr
express
monocyt
measur
day
admiss
invers
correl
infecti
complic
vs
p
previous
found
express
monocyt
hladr
patient
monocyt
also
associ
sepsi
hr
ci
decreas
hladr
express
indic
decreas
monocyt
respons
known
monocyt
deactiv
also
found
h
allel
polymorph
increas
risk
sepsi
tabl
cochranarmitag
trend
test
p
associ
time
sepsi
number
h
allel
assess
use
cox
model
regress
hazard
ratio
equal
per
ad
h
allel
ci
ad
iss
crp
day
model
hazard
ratio
sepsi
ci
per
ad
h
allel
hh
hr
patient
higher
risk
sepsi
rr
patient
hr
ci
p
adjust
iss
crp
day
h
allotyp
receptor
also
correl
percentag
monocyt
hladr
hh
variant
like
lower
hladr
express
compar
rr
variant
figur
found
associ
polymorph
monocyt
hladr
express
product
data
shown
find
sever
injur
cohort
patient
hypothes
polymorph
receptor
higher
affin
crp
could
revers
monocyt
deactiv
design
vitro
experi
look
experiment
model
monocyt
deactiv
effect
allel
polymorph
presenc
acut
phase
level
crp
volunt
r
allotyp
receptor
incub
significantli
decreas
hladr
express
monocyt
decreas
product
follow
lp
stimul
compar
control
volunt
r
allel
acut
phase
level
crp
abl
revers
monocyt
deactiv
increas
hladr
express
figur
increas
product
respons
subsequ
stimul
lp
compar
control
figur
volunt
h
allel
crp
unabl
attenu
monocyt
deactiv
trauma
patient
surviv
initi
injuri
resuscit
remain
elev
risk
morbid
mortal
character
rel
immunosuppress
increas
suscept
sepsi
overal
incid
sepsi
posttraumat
patient
report
incid
sepsi
patient
cohort
much
higher
like
reflect
higher
sever
injuri
mean
iss
find
similar
rate
describ
et
al
whose
cohort
incid
posttraumat
sepsi
mean
iss
gu
et
al
describ
incid
mean
iss
major
patient
develop
sepsi
pneumonia
specif
foci
infect
spite
routin
use
ventil
bundl
intub
trauma
patient
similar
find
croce
et
al
although
pneumonia
common
infecti
site
septic
complic
specif
cytokin
measur
cohort
associ
pneumonia
independ
analysi
data
shown
found
clinic
variabl
biochem
factor
genet
factor
correl
posttraumat
sepsi
sever
injur
cohort
patient
found
blood
transfus
within
first
hour
present
associ
develop
posttraumat
sepsi
find
recent
confirm
investig
torranc
et
al
found
transfus
blood
product
independ
associ
alter
pattern
gene
express
conclus
immunosuppress
respons
trauma
may
exacerb
blood
transfus
associ
increas
suscept
nosocomi
infect
demonstr
differ
overal
injuri
sever
score
patient
receiv
transfus
howev
significantli
higher
number
traumat
brain
injuri
patient
nontransfus
group
may
account
equival
iss
two
group
sinc
head
trauma
usual
associ
high
transfus
requir
clinic
variabl
use
predict
sepsi
multivari
model
found
iss
hr
per
unit
increas
ci
transfus
hr
ci
jointli
associ
sepsi
neither
age
gender
significantli
associ
sepsi
thu
adjust
model
use
iss
transfus
analys
found
elev
level
antiinflammatori
cytokin
proinflammatori
cytokin
well
chemokin
associ
increas
odd
develop
sepsi
elev
level
acut
phase
protein
crp
also
associ
posttraumat
sepsi
interestingli
solubl
associ
sepsi
popul
although
shown
predictor
burn
patient
piatkowski
et
al
monocyt
deactiv
measur
hladr
express
easili
measur
marker
immun
function
well
character
septic
trauma
patient
measur
monocyt
hladr
express
hospit
day
cohort
confirm
day
level
hladr
express
strong
invers
correl
septic
complic
also
found
allel
bind
crp
associ
septic
complic
sever
injur
cohort
hypothes
receptor
known
regul
monocyt
activ
function
host
defens
could
contribut
either
revers
prolong
monocyt
deactiv
patient
order
evalu
hypothesi
examin
monocyt
respons
polymorphismtyp
donor
experiment
model
monocyt
deactiv
presenc
absenc
acut
phase
level
crp
singl
nucleotid
polymorph
singl
base
chang
gene
occur
signific
frequenc
often
defin
popul
snp
code
region
gene
often
result
amino
acid
chang
may
alter
function
affect
protein
singl
nucleotid
polymorph
code
region
gene
appear
clinic
signific
receptor
contain
snp
result
function
allel
differ
bind
domain
h
allel
bind
igg
micromolar
affin
r
allel
bind
crp
micromolar
affin
function
differ
receptor
shown
alter
phagocyt
function
host
monocyt
clinic
result
differ
suscept
sever
diseas
found
elev
level
crp
sever
injur
patient
cohort
associ
infecti
complic
like
reflect
sever
injuri
howev
sinc
crp
level
known
elev
trauma
found
patient
h
allel
receptor
infecti
complic
compar
patient
r
allel
evalu
role
acut
phase
level
crp
vitro
experi
vitro
experi
abl
attenu
monocyt
deactiv
volunt
r
allel
treat
acut
phase
level
crp
find
suggest
common
genet
variat
receptor
may
contribut
infecti
suscept
trauma
patient
monocyt
deactiv
patient
r
allel
receptor
may
abl
revers
monocyt
deactiv
presenc
acut
phase
level
crp
h
allel
lack
abil
studi
necessari
delin
specif
mechan
crp
may
revers
deactiv
patient
studi
limit
number
patient
includ
analysi
well
conveni
sampl
enrol
introduc
possibl
select
bia
howev
confirm
effect
sever
independ
factor
previous
associ
increas
posttraumat
sepsi
give
support
find
propos
combin
clinic
variabl
earli
biochem
marker
genet
factor
may
aid
clinician
earli
identif
trauma
patient
risk
septic
complic
refer
web
version
pubm
central
supplementari
materi
hazard
ratio
confid
interv
predict
posttraumat
sepsi
inflammatori
marker
unadjust
cox
regress
analysi
b
cox
regress
analysi
adjust
confound
injuri
sever
score
blood
transfus
valu
day
biomark
shown
west
acut
phase
level
crp
revers
monocyt
deactiv
volunt
r
allel
receptor
evidenc
increas
hladr
express
monocyt
increas
hladr
express
monocyt
volunt
without
r
allel
hh
genotyp
r
allel
volunt
hh
volunt
p
p
acut
phase
level
crp
increas
product
follow
lp
stimul
ngml
deactiv
monocyt
r
allel
volunt
fail
affect
product
follow
lp
stimul
hh
volunt
r
allel
volunt
hh
volunt
p
p
